C. Ashby
Hematology · 2010–2015
A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Hematology — 32 citations into it
- Genetics — 29 citations into it
Whom C. Ashby trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- J. Goldman (in Hematology)
Papers from C. Ashby's perspective
Ordered by how strongly the researchers C. Ashby trusts endorse each paper. Same corpus, a different order for every researcher.
- Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. (Blood)
- Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Blood)
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
- The molecular biology of chronic myeloid leukemia. (Blood)
- Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (New England Journal of Medicine)
- Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
- Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. (New England Journal of Medicine)
- Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. (New England Journal of Medicine)
- Multidrug resistance in cancer: role of ATP–dependent transporters (Nature Reviews. Cancer)
- Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. (Cancer Cell)